important cause of visual loss in the developed world, [1] [2] [3] reported as causing 10% of cases of blindness in the United States 2 and as being the fifth, sixth, or seventh leading cause of blindness in various studies. 3, 4 Uveitis has a disproportionately high impact in terms of years of potential vision lost and economic effects because it often strikes at a younger age than common age-related eye disorders such as cataract, age-related macular degeneration, and glaucoma. 1 The proportion of blindness caused by uveitis may be declining, 3 presumably because of improving treatment. However, most patients managed in tertiary clinics experience visual loss at some point during their clinical course. 5 On the basis of clinical examination, uveitis can be classified into anterior uveitis, intermediate uveitis, posterior uveitis, or panuveitis-based on which portion of the eye is inflamed. 6, 7 The risk of vision loss is progressively higher along this spectrum. 5, 8 In developed countries, such as the United States, most intermediate uveitis and panuveitis cases and approximately one half of the posterior uveitis cases treated at uveitis practices, are presumed to be autoimmune, with no evidence of infection and a salutary response to corticosteroid and other anti-inflammatory therapies. 9 -20 Noninfectious uveitides encompass a wide variety of specific syndromes, each with specific diagnostic features. However, for noninfectious cases, corticosteroids are the mainstay of treatment in most instances, regardless of the specific syndrome diagnosed. [21] [22] [23] Use of systemic corticosteroids-with immunosuppressive drugs when indicated-historically has been the primary method advocated for control of severe cases of intermediate uveitis, posterior uveitis, and panuveitis. 22 The fluocinolone ace-tonide implant (0.59 mg; Bausch & Lomb, Inc, Rochester, New York, USA), 24, 25 introduced in 2005, is designed to be effective in controlling uveitis for 2.5 to 3 years, 26 and thus offers an alternative paradigm for the medium-or long-term management of these cases of uveitis. The relative efficacy and side-effect profiles of these alternatives have not been compared.
To provide evidence on the relative effectiveness and safety of systemic therapy with respect to fluocinolone acetonide implant therapy, we undertook a randomized, controlled clinical trial directly comparing these alternatives for the management of noninfectious intermediate uveitis, posterior uveitis, or panuveitis. This report describes the design of the trial and the baseline characteristics of the patients enrolled into the trial, providing new information about the demographic and clinical characteristics of intermediate uveitis, posterior uveitis, and panuveitis patients managed in tertiary uveitis practices.
METHODS

THE MULTICENTER UVEITIS STEROID TREATMENT (MUST)
trial is a randomized, partially masked, comparative multicenter clinical trial comparing the effectiveness and safety of local therapy with the fluocinolone acetonide implant (Bausch & Lomb, Inc) versus systemic therapy with oral corticosteroids and immunosuppressive drugs when indicated 22 for patients with severe noninfectious intermediate uveitis, posterior uveitis, or panuveitis. The specific aims of the trial are: (1) to compare visual outcomes between implant therapy and systemic therapy; (2) to compare effectiveness of these treatment strategies for controlling uveitis and avoiding the accumulation of complications thereof over time; (3) to compare rates of both ocular and systemic side effects; and (4) to compare quality of life between treatment strategies. Cost-effectiveness analysis 27 also will be conducted. The overall goal is to ascertain the relative benefits and risks of the alternative therapies and the incremental cost-effectiveness of the 2 treatment approaches.
A detailed description of the study methods-including the rationale for the specific methodologies and treatment approaches selected-is provided as supplemental text (available online at www.AJO.com). In brief, the MUST trial is designed to detect a difference between randomly assigned treatment groups of 7.5 letters (1.5 lines) in mean (eye-specific) change in logMAR visual acuity from baseline to follow-up at 2 years. Sample size calculations estimated that enrollment of 250 patients would provide 90% power to detect this difference, allowing for a type 1 error probability of 0.05, assuming 10% losses to follow-up. Eligible patients had active or recently active (within 60 days) intermediate uveitis, posterior uveitis, or panuveitis that was judged to require systemic corticosteroid therapy (eligibility criteria are given in Supplemental Table 1 ).
These are the forms of uveitis for which the fluocinolone acetonide implant therapy is indicated and are forms of uveitis for which systemic therapy as studied in the trial is commonly indicated. 22 Because one of the alternative treatments is systemically administered, and the goal of the trial was to compare alternative treatment strategies at the level of the patient (including quality-of-life analysis), patients (rather than eyes) were randomized to the alternative treatments. Random treatment assignments to implant or systemic therapy (allocation ratio, 1:1) were stratified by clinical center. Within each clinical center, randomization also was stratified by the type of uveitis (intermediate uveitis vs posterior uveitis or panuveitis) because visual acuity outcomes likely differ between these disease categories 8 (see Supplemental Figure 1 ).
Implant therapy (see Supplemental Figure 2 ) consisted of treatment with the commercially available fluocinolone acetonide 0.59-mg implant (Retisert; Bausch & Lomb, Inc) in each eye with uveitis of sufficient severity to justify treatment with systemic corticosteroids. After quieting of the anterior chamber to less than grade 1ϩ of anterior chamber cells, 7 implantation was performed by a studycertified surgeon using a standard technique 25 within 28 days of randomization. When applicable, the second eye was implanted within 28 days thereafter using the same approach. Eyes initially receiving systemic corticosteroid or immunosuppressive therapy were tapered off of such therapy after implant placement, generally within several weeks, but slowly enough to avoid complications related to adrenal suppression resulting from corticosteroid therapy. Eyes in which a reactivation of uveitis developed after implantation were reimplanted using the same approach; the choice to remove or leave in place a preexisting implant is left to the best medical judgment of the treating surgeon.
Systemic therapy consisted of oral corticosteroid therapysupplemented when indicated by immunosuppression-in accordance with expert panel recommendations. 22 Patients with active uveitis at baseline were started on prednisone 1 mg/kg per day up to a maximum adult oral dose of 60 mg/day (see Supplemental Figure 3 ), which was continued until the uveitis was controlled or until the patient had been receiving this dose of prednisone for 4 weeks. After suppression of uveitis was achieved, oral corticosteroids were tapered, according to specified guidelines. Patients whose uveitis already had been controlled within the 60 days before enrollment started at their current prednisone dose and tapered their prednisone dose in the same manner. When immunosuppressive therapy was indicated (see Supplemental Figure 3 and Supplemental Text), the choice of which immunosuppressive drug to use was not dictated by the trial to permit selection of the agent with the best side-effect profile for an individual patient. However, the treatments selected were administered in accordance with expert panel guidelines, including laboratory monitoring for potential toxicities. 22 Many additional treatment protocol details are given in the Supplemental Text (available at www.AJO.com).
Because the primary goal of therapy for uveitis is to preserve vision, the primary outcome by which success is judged in the MUST trial is best-corrected visual acuity, as measured by standard logarithmic (Early Treatment Diabetic Retinopathy Study) visual acuity charts. 38 Other outcomes evaluated pertain to control of intraocular inflammation, the occurrence of ocular complications of uveitis or of therapy, the occurrence of systemic complications of therapy, and self-reported quality of life. Imaging studies used and the representative features evaluated by them include: lens photography (cataract), fundus photography (macular edema, epiretinal membranes, optic nerve morphologic features, chorioretinal lesions, vascular occlusions), Stratus optical coherence tomography ([Carl Zeiss Meditec, Inc, Jena, Germany]; macular edema, vitreoretinal interface abnormalities including epiretinal membrane), and fluorescein angiography (macular edema, general health-related quality of life as measured by the Short Form 36-item questionnaire, 41, 42 and vision-related quality of life as measured by the 25-item National Eye Institute Visual Function Questionnaire. 43 Masking is applied to the determination of visual acuity (beginning 6 months after randomization, to avoid unmasking by visible postoperative changes), those outcomes based on photographic reading, and diagnosis of glaucoma by an outcomes committee. Because sham surgery is not performed, masking during ascertainment of the other outcomes is not feasible.
•
STATISTICAL METHODS FOR BASELINE ANALYSIS:
Patient, ocular, and imaging characteristics at randomization were summarized for the population as a whole and were stratified by uveitis type at enrollment based on data collected as of October 1, 2009. For patient characteristics, differences between the strata were compared using the Wilcoxon rank-sum test for continuous variables and the chi-square test-or Fisher exact test if appropriate-for categorical variables. When the unit of analysis was the eye, linear, logistic, or multinomial regression models were used to compare strata after adjusting for the excess correlation between eyes from the same individual using generalized estimating equationsderived methods for continuous, binary, and multinomial outcomes, respectively. 35 
RESULTS
BETWEEN DECEMBER 6, 2005, AND DECEMBER 9, 2008, 255
patients were enrolled at 23 clinical centers and were randomized to implant (129 patients) or systemic (126 patients) therapy. Ninety-seven patients (180 eyes with uveitis) were enrolled in the intermediate uveitis stratum, and 158 (301 eyes with uveitis) were enrolled in the posterior uveitis or panuveitis stratum (see Table 1 ). The age and sex distributions were similar between groups, but the race or ethnicity distribution differed significantly in that Hispanic persons were more likely to have posterior uveitis or panuveitis than intermediate uveitis. EuroQol visual analog scale 40 health utility scores were similar between groups: the mean overall score (74.1; 95% CI, 71.6 to 76.6) was reduced with respect to normative population values 59 (normative score, 80.0; standardized to the MUST population for age group and sex). Eighty-nine percent of patients had bilateral uveitis, with a similar proportion in both strata. In total, 21% of patients had a systemic inflammatory disease in association with uveitis, 15% in the intermediate uveitis group versus 25% in the posterior uveitis or panuveitis group (P ϭ .05). Patients with posterior uveitis or panuveitis were substantially more likely to have Behçet's disease than patients with intermediate uveitis (5% vs 0%; P ϭ .03). Osteoporosis, defined as a T score less than Ϫ2.5 on DEXA scanning of the spine (L2 to L4) and left femoral neck, 37 was present among 8% of patients in both groups at baseline.
Among 481 eyes with uveitis, 180 (37%) were in the intermediate uveitis stratum and 301 (63%) were in the posterior uveitis or panuveitis stratum (see Table 2 ). The distributions of severity of vitreous haze and vitreous inflammatory cells were similar at baseline between the 2 groups. Intraocular pressure also was similar in the 2 groups, with most patients having average intraocular pressure at baseline; patients with high intraocular pressures and uncontrolled glaucoma had been excluded from enrollment (see Supplemental Table 1 ). Approximately half of eyes with uveitis had low vision (best-corrected visual acuity worse than 20/40), and approximately 16% were legally blind (best-corrected visual acuity of 20/200 or worse), with a similar distribution across intermediate uveitis versus posterior uveitis or panuveitis cases. Considering the better eye of each patient, including eyes without uveitis, 31% had low vision and 5% were legally blind at baseline. As expected, visual field reductions were more extensive in the posterior uveitis or panuveitis group than the intermediate uveitis group (average Humphrey mean deviations, Ϫ8.7 vs Ϫ6.4 respectively; P Ͻ .01). Overall, 75% of patients had a mean deviation of Ϫ3.0 or worse.
Regarding structural ocular abnormalities associated with inflammation, as ascertained by image grading, 41% of eyes were pseudophakic at baseline in each group, and 39% of the remainder were judged to have a lens opacity at baseline (see Table 3 ). The mean macular thickness tended to be greater in the intermediate uveitis group than in the posterior uveitis or panuveitis group (288 vs 256 m; P ϭ .09). Cystoid edema was present in the central macula in 38% of eyes, with a similar distribution across intermediate uveitis and posterior uveitis and panuveitis cases. Fluorescein angiographic grading demonstrated a similar degree of macular leakage in the 2 groups, with a mean of 3.5 Ϯ 5.3 disc areas. By grading of color photographs, epiretinal membranes were significantly more common in the intermediate uveitis group than the posterior or panuveitis group (57% vs 42%; P ϭ .01), although the difference arose from a greater frequency of subtle epiretinal membranes in the former group, whereas both groups had a similar proportion with definite epiretinal membrane (11% vs 13%; P ϭ .63). Macular pigmentary disturbances were more common in posterior uveitis or panuveitis cases than intermediate uveitis cases (39% vs 16%; P Ͻ .01). Subretinal fibrosis (6% vs. 1%; P ϭ .05) and disc swelling (6% vs 1%; P ϭ .03) were infrequent, but were more common in the posterior uveitis and panuveitis group than in the intermediate uveitis group.
DISCUSSION
THE 2005 INTRODUCTION OF THE FLUOCINOLONE IMPLANT,
which is effective for controlling severe posterior segment ocular inflammation over long periods, 24, 25 raised questions about the relative merits of local therapy with the fluocinolone acetonide implant versus systemic therapy for intermediate uveitis, posterior uveitis, and panuveitis. Implant therapy is expected to be highly effective for control of inflammation while the implant continues to deliver drug, but is expected to result in a high incidence of cataract and intraocular pressure elevation requiring treatment. 24, 25, 28 Systemic therapy is likely to have more systemic side effects 22 and more relapses of inflammation-because the minimum suppressive prednisone dose is determined by iterative tapering-but is likely to result in a lower incidence of local complications of corticosteroid therapy 60, 61 and may have systemic or ocular benefits by addressing more comprehensively the autoimmunity that likely underlies many of these cases. The MUST trial is designed to provide guidance as to whether one of these paradigms is superior.
Given that the proportion of eyes with bilateral uveitis and the number of patients actually enrolled was higher than expected (see Supplemental Text, available at www. ajo.com), the trial will have greater statistical power than originally estimated, and therefore is expected to answer the questions of interest effectively. The trial is designed to evaluate both the benefits and the side effects (local and systemic) of the alternative treatments. Because local side effects are expected to be more frequent in the implant group 24, 25, 28 and systemic side effects are expected to be more frequent in the systemic therapy group, 22 quality-oflife results may be highly informative regarding the merits of the alternative treatments. Cost and cost-effectiveness analyses 27 will be performed to determine the relative costs of each treatment approach and to determine the incremental cost of each incremental gain in benefit with the superior treatment. Enrollment of the trial was completed in December 2008, and the primary results at the 2-year follow-up can be expected shortly after that follow-up point is reached (early 2011).
In baseline observations from the MUST trial, intermediate uveitis was diagnosed in a lower proportion of Hispanic persons than white or black persons; because clinical trial patients are not necessarily sampled in a manner representative of the general population, it is unclear whether this difference in the distribution of site of inflammation by race/ethnicity is meaningful. The results also suggest that systemic inflammatory disease is less commonly associated with intermediate uveitis than with posterior uveitis or panuveitis, confirming clinical impressions. Nearly 10% of patients had osteoporosis at baseline, emphasizing the importance of following bone mineral density testing and providing appropriate preventive and remedial treatment in patients for whom systemic corticosteroid therapy will be used. 22, 37 At enrollment, patients and eyes had a high prevalence of reduced visual acuity and of ocular complications of uveitis, and patients reported a substantially reduced quality of life, emphasizing the significant adverse consequences of intermediate uveitis, posterior uveitis, and panuveitis. Using a time tradeoff methodology, the losses of health utility associated with a reduction of vision to the 20/60 to 20/100 range and to 20/200 or worse have been estimated as being a 28% and a 39% reduction in the quality of life, respectively. 62 Our patients were observed to have health utility similar to that associated with visual acuity in the 20/60 to 20/100 range, although only 31% had low vision in their better eye, suggesting that uveitis may have additional health impact over and above its effect on vision, perhaps via symptoms of inflammation unmeasured by visual acuity, side effects of treatment, the impact of associated systemic disease, or a combination thereof.
Among eyes with uveitis, visual acuity was similar in the intermediate uveitis group and the posterior uveitis and panuveitis group. Overall visual sensitivity as measured by automated visual field testing was reduced in both groups-likely reflecting the impact of macular edema and other complications of uveitis-but was significantly lower in the posterior uveitis and panuveitis group, probably reflecting the additional impact of chorioretinal lesions. Lens opacities were common in both groups, with 80% either pseudophakic or with lens opacity at enrollment, indicating that there is a high risk of cataract in severe uveitis cases, although likely in part reflecting a greater willingness to consider randomization to implant treatment in pseudophakic or cataractous eyes, given that implant therapy is expected to cause cataract in nearly all phakic eyes. 25, 63 Eyes with intermediate uveitis tended to have a higher prevalence of macular edema and epiretinal membrane, which may reflect a practice pattern of using the occurrence of such events as an indication for more aggressive anti-inflammatory therapy. Other complications of posterior segment inflammation were unusual in both groups.
In addition to addressing the clinical questions regarding treatment approaches, the MUST trial will provide the first large, prospective data set of long-term, longitudinal observations on the outcomes of patients with severe uveitis, potentially yielding information regarding the clinical epidemiologic characteristics of complications of uveitis. The large number of patients at baseline with reduced visual acuity, and other uveitis-related problems such as macular edema and epiretinal membrane, suggests that the study will provide substantial power to evaluate several important open questions for severe cases of these types of uveitis, including the risk of both improvement in and loss of visual acuity, the incidence of posterior segment complications of uveitis, and the incidence of ocular surgery, among others.
Limitations of the study design arise primarily from heterogeneity of the forms of uveitis involving the posterior segment. Posterior uveitis and panuveitis particularly consist of a wide variety of inflammatory entities, which potentially may be heterogeneous in their response to one or both of the treatments. Results from the Bausch & Lomb BLP 415-001 trial of the fluocinolone acetonide implant suggest that implant therapy is highly effective across a broad array of uveitis patients, 24, 25 suggesting that heterogeneity is not likely to be relevant for the implant arm. The benefits of systemic anti-inflammatory therapy have been indicated in several specific disease states, 61,64 -66 also suggesting a broad usefulness of this therapeutic approach. Because patients are being enrolled at tertiary uveitis centers, where treatments of this nature often are administered, it is likely that more severe cases were enrolled than might have been enrolled at less specialized centers. However, because qualitative treatment-disease severity interactions are unlikely, the relative risk of change in vision likely also should be sufficiently generalizable to be useful in determining which treatment approach is best in a less specialized setting. Finally, because patients enrolled in clinical trials usually are not typical patients, the experience of MUST trial patients may differ in some ways from that of future patients. However, the strengths of the randomized clinical trial methodology with respect to alternative designs outweigh this limitation, leaving the clinical trial approach as the most favorable design available for evaluating the relative merits of alternative treatments for specified disease diagnoses.
In summary, the MUST trial is a phase 4 effectiveness trial that aims to evaluate whether fluocinolone acetonide implant therapy or systemic corticosteroid therapy (supplemented when indicated by use of immunosuppressive drugs) is superior for the management of noninfectious intermediate uveitis, posterior uveitis, and panuveitis. Enrollment was completed in December 2008, and the primary 2-year follow-up results can be expected in early 2011. Observations from the baseline characteristics of the MUST patients suggest that these patients have a high prevalence of visual loss, cataract or pseudophakia, macular edema, and epiretinal membrane, and a reduced overall quality of life greater in degree than would be expected based on loss of visual acuity alone. 
SUPPLEMENTAL TEXT: DESIGN DETAILS FOR THE MULTICENTER UVEITIS STEROID TREATMENT TRIAL
• Eligibility: Eligibility criteria are given in Supplemental Table 1 . Eligible patients had active or recently active (within 60 days) intermediate uveitis, posterior uveitis, or panuveitis-the forms of uveitis for which the fluocinolone acetonide implant therapy is indicated. These are forms of uveitis for which systemic therapy commonly is indicated. 22 Because of safety considerations, patients who were pregnant or breastfeeding, those younger than 13 years, those with uncontrolled glaucoma or diabetes, those with allergies to required study medications, those with scleritis or ocular toxoplasmosis, and those with known immunodeficiency syndromes were excluded. Because some episodes of substantially elevated intraocular pressure (IOP) were expected to occur in the implant arm, 28 patients with advanced glaucoma who might experience irreversible damage from such an IOP spike also were excluded. Patients with associated systemic inflammatory diseases likely to require systemic therapy for a nonocular indication were excluded on the grounds that systemic therapy would be preferable to implant therapy. Patients were required to have a visual acuity of hand movements or better in at least 1 eye with uveitis, because eyes with visual acuity worse than this level may not benefit enough from treatment to justify the potential risks of the alternative therapies.
• Sample Size: The primary analysis for the MUST trial is to compare the mean eye-specific change in logarithm of the minimum angle of resolution visual acuity from baseline to follow-up at 2 years between the randomly assigned treatment groups. Mean change in visual acuity was chosen as the primary outcome because of an increasing consensus among the ophthalmology clinical trials community in favor of designing clinical trials to detect a difference in the mean visual acuity rather than the proportion achieving a given number of lines of visual acuity lost or gained 29 Based on considerations that previous clinical trials demonstrating a difference of approximately 7.5 letters (equivalent to 1.5 lines on a logarithmic visual acuity chart) 30 in mean visual acuity between treatment groups have resulted in the widespread adoption of the new treatments, [31] [32] [33] [34] the MUST trial is designed to detect at least a 7.5-letter difference in visual acuity between groups, with at least 90% power.
For the sample size calculation, the number of independent observations needed (assuming only 1 eye from each patient) was adjusted to take into account the percent of patients expected to have bilateral disease at baseline (estimated as 67%) and the expected between-eye correlation in acuity changes for involved eyes (conservatively estimated to be 0.4). 35 We estimated the standard deviation of change in visual acuity to be 16 letters (3.2 lines). Based on these assumptions, and allowing for a crossover rate of 10%, a sample size of 250 (125 patients SUPPLEMENTAL per group) was projected to have a power of 91% with a 2-sided type 1 error rate of 5% to detect at least a 7.5-letter difference in visual acuity between groups.
• Randomization: Uveitis may affect one or both eyes.
Implant therapy is given to one eye at a time, but systemic treatment affects both eyes simultaneously. Because one of the alternative treatments is systemically administered, and because the goal of the trial was to compare alternative treatment strategies at the level of the patient (including quality-of-life analysis), patients (rather than eyes) were randomized to the alternative treatments. Random treatment assignments (allocation ratio, 1:1) were stratified by the type of uveitis (intermediate uveitis vs posterior uveitis or panuveitis) because visual acuity outcomes likely differ between these disease categories 8 and also by clinical center to balance any potential effects of varying protocol implementation or population differences at the clinics across treatment arms (see Supplemental Figure 1) . The Rallocate procedure 36 in Stata software version 9 (StataCorp, College Station, Texas, USA) was used to generate permuted block randomization tables with variable block sizes for each stratum level. The treatment assignment procedure was implemented using a web-based system that returned treatment assignments in real time after completion of eligibility checks. Randomization was conducted after obtaining informed consent and entering required baseline data. Before randomization, institutional review board approval was obtained by each participating center. The MUST trial is registered at clinicaltrials.gov (identifier NCT00132691). (using topical and/or periocular corticosteroids, and/or systemic corticosteroid therapy when the first 2 approaches are judged insufficient), the protocol called for surgical implantation of an implant by a MUST-certified surgeon using a standard technique 25 under conventional anesthesia within 28 days of randomization in the first eye. When applicable, the second eye was implanted within 28 days thereafter using the same approach. For second eyes that initially did not meet criteria for implantation, but subsequently worsened to the point where systemic corticosteroid therapy would be justified, implantation was performed at the time the eye met such criteria in the same manner. Eyes in which a reactivation of uveitis developed after implantation were reimplanted (regardless of when the reactivation occurred with respect to the original surgery); eyes in which a second reactivation developed within 18 months after reimplantation were managed according to best medical judgment. Eyes also were managed according to best medical judgment when any of the following occurred: (1) the patient required systemic prednisone or immunosuppressive therapy for systemic indications; (2) toxicity of implant therapy occurred; or (3) inflammation was not controlled initially after implantation. Eyes initially receiving systemic corticosteroid or immunosuppressive therapy were tapered off of such therapy after implant placement-generally within several weeks, but slowly enough to avoid complications related to adrenal suppression from corticosteroid therapy. Eyes for which additional intraocular surgery-such as cataract surgery-was needed at baseline (and so noted before randomization on an enrollment form) were permitted under the protocol to have the other intraocular surgery combined with implant surgery. However, vitrectomy surgery to clear vitreous opacities was not performed on the grounds that implant therapy was expected to clear such opacities.
• Systemic Treatment Protocol: Systemic therapy consisted of oral corticosteroid therapy-supplemented when indicated by immunosuppression-in accordance with expert panel recommendations. 22 Patients with active uveitis at baseline were started on prednisone 1 mg/kg per day up to a maximum adult oral dose of 60 mg/day (see Supplemental Figure 3 ), which was continued until the uveitis was controlled, or until the patient had been receiving this dose of prednisone for 4 weeks.
After suppression of uveitis was achieved, oral corticosteroids were tapered, according to the following guidelines: (1) 10 mg/day decrements each week to 40 mg daily; (2) 5 mg/day decrements each week to 20 mg daily; (3) 2.5 mg/day decrements every week to 10 mg daily; (4) 2.5 mg/day decrements every 2 weeks until off prednisone. Patients whose uveitis already had been controlled within the 60 days before enrollment started tapering from their current prednisone dose and tapered their prednisone dose in the same manner.
Immunosuppressive therapy was used when: (1) uveitis was not controlled on corticosteroids alone; (2) maintenance of suppression of uveitis required a prednisone dose of more than 10 mg/day or a dose sufficient to cause intolerable side effects; (3) for specific diseases known to respond poorly absent initial immunosuppressive therapy, or (4) a combination thereof. 22 The choice of which immunosuppressive drug to use was not dictated by the trial to permit selection of the agent with the best side-effect profile for an individual patient. However, the immunosuppressive treatment(s) selected was administered in accordance with expert panel guidelines, including laboratory monitoring for potential toxicities. 22 Because of the potential additive therapeutic effect of antimetabolites and T-cell inhibitors, a second immunosuppressive drug of the alternative class was recommended for patients not meeting treatment goals with 1 immunosuppressive drug. Alkylating agents (cyclophosphamide and chlorambucil), although given in conjunction with prednisone, were not to be combined with other immunosuppressive drugs because of the potential for substantially increased toxicity with such combinations.
When needed (i.e., for patients who had flare-ups of uveitis while still taking oral corticosteroids), tapering of prednisone was repeated iteratively: the dose of prednisone was raised to a level sufficient to control the inflammation each time a flare-up of inflammation occurred and then tapered until either uveitis was controlled without prednisone or until a minimal suppressive dose of prednisone (with or without concomitant immunosuppressive therapy) was identified SUPPLEMENTAL FIGURE 3. Systemic treatment algorithm for the Multicenter Uveitis Steroid Treatment Trial.
that was effective for maintaining suppression of inflammation and had an acceptable side-effect profile. If 2 iterations of tapering in the presence of an immunosuppressive agent failed to achieve a tolerable minimal suppressive prednisone dose, treatment was to be directed by best medical judgment. Likewise, if the suppressive dose proved to be too high to have a favorable side-effect profile when an alkylating agent was used as the initial immunosuppressive agent, treatment thereafter was directed by best medical judgment.
After 6 months of successful suppression of uveitis using systemic therapy, an attempt was made to taper the prednisone further with monthly decrements following the steps above. If such tapering resulted in reactivation of uveitis, the prednisone dose was raised sufficiently to control the uveitis, and then tapered back to the suppressive dose, after which the patient was to be maintained on suppressive systemic therapy at the suppressive dose for 12 months before further tapering attempts.
While receiving oral corticosteroids, patients received calcium and vitamin D supplementation to minimize the incidence of osteoporosis. 37 Patients in whom osteoporosis developed were referred for treatment, according to guidelines of the American College of Rheumatology. 37 Patients in whom hypertension or diabetes developed as a result of systemically administered drugs also were referred for appropriate management.
• Ancillary Treatment: Patients in both treatment arms were allowed topical corticosteroid therapy as indicated by best medical judgment, given according to study guidelines. Given the severe nature of the uveitis of patients enrolled in this trial, and given the limited penetration of topical corticosteroids past the anterior chamber to the primary site of inflammation in these patients, 22 these drops are unlikely to have a substantial effect on the major causes of visual loss.
The protocol also permitted the use of periocular corticosteroid injections (triamcinolone acetonide, 40 mg) when indicated for the following circumstances: (1) for patients randomized to implant therapy, periocular corticosteroids could be given before implantation to suppress intraocular inflammation rapidly before surgery; or (2) for persistent or refractory macular edema in either group. Periocular corticosteroids could be given either via the posterior subTenon route or via the orbital floor route. Ancillary intravitreous corticosteroid therapy also could be given for the same indications when periocular corticosteroid injections were likely to fail or had failed. The protocol directed that periocular and intraocular corticosteroid injections should not be given repetitively on a routine basis as a primary form of therapy.
• Data Collection and Follow-up: Patients enrolled in the MUST trial have visits for data collection at baseline, at 1 and 3 months after randomization, and then quarterly until the end of the trial (see Supplemental Table 2 ). Other than the visit 1 month after randomization (which is excluded from the efficacy analysis), study visits should not be conducted within 1 month of ocular surgery (e.g., implant surgery) to avoid biasing visual acuity measurements downward in recently operated eyes, which are expected to have reduced visual acuity transiently in the early postoperative period. Patients generally receive more frequent visits for clinical care. Data regarding treatment changes and events occurring between study visits are collected at the subsequent study visit, except for adverse events that meet requirements for expedited reporting. Visual acuity x x x x x x x x x x Goldmann tonometry x x x x x x x x x x Ophthalmic examination For women who were able to become pregnant.
• Outcomes: Because the primary goal of therapy for uveitis is to preserve vision, the primary outcome by which success is judged in the MUST trial is bestcorrected visual acuity. Other outcomes evaluated pertain to control of intraocular inflammation, the occurrence of ocular complications of uveitis or of therapy, the occurrence of systemic complications of therapy, and self-reported quality of life (QOL).
Masking is applied to the determination of visual acuity, those outcomes based on photographic reading, and diagnosis of glaucoma by the Glaucoma Outcomes Committee. Because sham surgery is not performed, masking during ascertainment of the other outcomes is not feasible.
The primary outcome-best-corrected visual acuity-is measured every 3 months at study visits under standardized lighting conditions by certified study examiners with best refractive correction in place, using standard logarithmic (Early Treatment Diabetic Retinopathy Study [ETDRS]) visual acuity charts. 38 At the 6-month visit (by which time the impact of implant surgery rarely would be visible in a darkened room) and subsequently, these measurements are made by examiners unaware of treatment assignment. Eye-specific outcomes such as visual acuity are followed as by-eye variables, an approach that provides more information than a by-patient analysis and avoids the problem of having to select a study eye. In the ETDRS system, 15 letters is equal to a change of 3 lines of visual acuity, for example, from 20/40 to 20/20 or vice versa, a halving or doubling of the visual angle 30 ; a change of 7.5 letters corresponds to a 25% decrease or 50% increase in the visual angle.
Secondary outcomes for the MUST trial include evaluation of inflammatory and morphologic characteristics of enrolled eyes, which are measured longitudinally throughout the course of the study (see Appendix, below). Assessment is performed by unmasked ophthalmologist investigators and by masked grading of imaging studies. The methods used and the representative features evaluated by them include: lens photography (cataract), fundus photography (macular edema, epiretinal membranes, optic nerve morphologic features, chorioretinal lesions, vascular occlusions), Stratus optical coherence tomography (macular edema, vitreoretinal interface abnormalities including epiretinal membrane), and fluorescein angiography (macular edema, vascular leakage, perfusion abnormalities, choroidal neovascularization). Healthrelated quality-of-life data also are assessed, including health utility as measured by the EuroQol 5-dimension and Visual Analog Scale scores, 39, 40 general health-related QOL as measured by the Short Form 36-item questionnaire, 41, 42 and vision-related QOL as measured by the 25-item National Eye Institute Visual Function Questionnaire. 43 
• Data and Safety Monitoring: The Data and Safety
Monitoring Committee (DSMC)-an independent board appointed by and advisory to the study funding agency (the National Eye Institute)-is responsible for ongoing review of efficacy and safety data, policy and ethical issues, and study performance. Members of the DSMC include 2 ophthalmologists, 2 rheumatologists, 2 biostatisticians, and an ethicist. The DSMC meets twice yearly with the option for ad hoc meetings if required. An O'Brien Fleming ␣ spending function was used to develop guidelines for stopping the trial. The DSMC has planned for 3 formal analyses of the efficacy data, after 50%, 75%, and 100% of participants have been followed up for 2 years. These guidelines call for stopping the trial early only if large differences between groups in the mean change in visual acuity from baseline-12.5 to 15 letters or more-are observed at the interim analyses. One of the physician members of the DSMC reviews adverse event data between DSMC meetings, which are reviewed first by a Coordinating Center ophthalmologist and safety officer.
• Study Organization: 
APPENDIX: OUTCOME DEFINITIONS AND PLANNED ANALYSES FOR THE MULTICENTER UVEITIS STEROID TREATMENT TRIAL
• Visual Acuity: Best-corrected visual acuity score is measured at every study visit under standardized lighting conditions by certified study examiners with best refractive correction in place, using logarithmic (ETDRS) visual acuity charts 38 (as described above). The design outcome is based on change by 2 years' follow-up in visual acuity (number of letters read) from baseline in eyes meeting trial inclusion criteria at baseline.
In addition to the primary analysis, visual acuity data are to be analyzed in several different ways: (1) Uveitis is judged to be inactive when anterior chamber cells are graded as 0 or 0.5ϩ and vitreous haze is graded as 0; gradings of 1ϩ or higher on either scale are interpreted as indicated that the uveitis is active. The examining clinician also is asked to grade the uveitis as active, mildly active, or inactive based on her or his own judgment. For rare uveitic conditions, such as serpiginous choroidopathy, in which inflammation may be limited to the choroid and retina, clinical judgment of activity is substituted for the composite score based on anterior chamber cells and vitreous haze.
Clinical examination data regarding consequences of intraocular inflammation also are noted at every visit, including anterior chamber flare (graded over an ordinal scale of 0, 1ϩ, 2ϩ, 3ϩ, 4ϩ), 44 and the presence or absence of posterior synechiae, preretinal neovascularization, choroidal neovascularization, epiretinal membrane or macular pucker, macular edema, optic nerve swelling, pars plana exudation, and retinal detachment. The presence of peripheral anterior synechiae and angle closure are documented by annual gonioscopy. If present, the extent (in degrees) of posterior synechiae and of peripheral anterior synechiae or angle closure are recorded. Cataract grading is performed by the Reading Center from slit-lamp lens photographs and red reflex photographs of the lens plane (see below).
• Retinal Morphologic Features: To document the ocular abnormalities of uveitis and its complications, MUST trial clinical centers obtain fundus photographs, fluorescein angiograms, optical coherence tomography (OCT) scans, and lens photographs using standardized protocols generated by the Reading Center at the University of Wisconsin, Madison. Images are graded at the Reading Center according to standardized protocols for status of and change in ocular morphologic features. The resultant data are summarized into analysis variables and are transmitted to the Coordinating Center.
Retinal morphologic features often are altered pathologically as a result of intermediate uveitis, posterior uveitis, or panuveitis. A common morphologic change, and the most common cause of vision loss in uveitis, is the occurrence of macular edema. Therefore, measurement of macular edema is a primary goal of ocular image analysis. The presence versus absence of macular edema is determined by fluorescein angiography (FA) and OCT. When edema is present, severity of fluorescein leakage and of cystoid spaces is assessed using a modification of the ETDRS protocol. The area of retinal thickening and of cystoid spaces found on concurrently graded FA and color fundus photographs also is noted. The extent of fluorescein leakage is noted in disc areas. Central macular thickness is measured by OCT, as is the volume within the ETDRS circle. Other OCT features consistent with macular edema, such as cystoid spaces, are graded in terms of presence and extent. These morphologic measures are expected to correlate with visual acuity.
Additional retinal morphologic features (with the image from which it is derived in parentheses) being graded include vascular nonperfusion (FA), choroidal neovascularization (FA), preretinal neovascularization (color fundus photographs, FA), retinal detachment (fundus photo, FA), optic disc edema (fundus photo, FA), glaucomatous optic disc changes (enlarged cup-to-disc ratio, notching or thinning of the disc rim, disc pallor, and disc hemorrhage; stereo fundus photographs), vitreoretinal interface abnormalities (such as epiretinal membrane) and their relationship to macular edema (OCT and fundus photography), and chorioretinal lesions (fundus photography, FA with sweep fields). Morphologic features in most cases are measured as dichotomous variables (present or absent), and if present, their extent is graded.
• Quality of Life: As an ocular disease, uveitis is expected to affect QOL primarily through its impact on vision. However, systemic therapy and associated systemic disease may have effects on perceived general health-related QOL and health utility. In addition, because the effect of vision loss on general well-being is profound, the effect of uveitis on general well-being may be substantial despite localization of disease to the eye. The National Eye Institute Visual Function Questionnaire is an instrument designed to be responsive to the effects of eye diseases on QOL, particularly addressing vision-related QOL. It is based on aspects of vision and ocular symptoms. The National Eye Institute Visual Function Questionnaire has been demonstrated to give valid and reliable results across a variety of ocular conditions 43, 45 and is a widely used instrument for measurement of vision-related QOL. The Medical Outcomes Study Short Form Health Survey is an instrument measuring general healthrelated QOL that has been demonstrated to fulfill rigorous validity and reliability standards. 41, 42 It is the instrument most commonly used to measure general health-related QOL in clinical studies. 46 The EuroQol is a generic health index widely used in clinical research to calculate a health utility, 39 the measurement of which has been recommended for all clinical trials by the Panel on Cost Effectiveness in Health and Medicine. 27 A health utility score is useful as a summary indicator of a patient's self-perceived general health status, which can be used to compare the impact of uveitis (and its treatment) relative to the impact of other diseases. Health utility also will provide the primary effectiveness measure for costeffectiveness analysis. The MUST trial QOL battery consists of these 3 instruments, all available in both English and Spanish.
• Potential Complications of Study Treatment: Both randomized treatment approaches are expected to result in side effects. The relative occurrence of such events are key results of the study, which will play an important part in interpretation of the overall results. Specific complications to be evaluated prospectively are described below. An adverse events reporting system also is used to ascertain the occurrence of both anticipated and unanticipated adverse events. Ocular side effects of treatment anticipated to occur with substantial frequency in the MUST trial include cataract and glaucoma, which are common side effects both of uveitis and of corticosteroid therapy. Occurrence of complications of intraocular surgery-such as endophthalmitis, vitreous hemorrhage, and implant extrusion-most likely will be uncommon, but are important. Because ocular adverse events will be important for comparison of the alternative treatments, detailed measurements are being obtained.
Systemic therapy with corticosteroids or immunosuppressive (corticosteroid-sparing) agents can be associated with adverse systemic side effects. Because the occurrence of systemic side effects with systemic therapy is an important element of the rationale for using the fluocinolone acetonide implant, detailed data are collected on anticipated potential complications.
• Elevated Intraocular Pressure and Glaucoma: IOP elevation and glaucoma may be either a complication of uveitis itself or may be corticosteroid induced. IOP is measured using the protocol followed by the Collaborative Initial Glaucoma Treatment Study, before gonioscopy or dilation. 47 A certified technician operates a Goldmann applanation tonometer, while a second observer records the findings. The second observer then resets the tonometer, and the measurement is repeated. If the 2 measures differ by 2 mm Hg or more, then a third measurement is made to adjudicate the discrepancy. Tono-Pen (Mentor Ophthalmics, Norwell, Massachusetts, USA) IOP measurement is acceptable when Goldmann tonometry cannot be performed. IOP measurements of more than 21 mm Hg are considered to be elevated, and measurements higher than 30 mm Hg are considered to be highly elevated. Elevations of IOP and the outcomes of these events are monitored.
Diagnosis of glaucoma is made through the integration of several inputs. Stereo optic nerve photographs are graded by the Reading Center. Humphrey visual field testing is used to screen for glaucomatous visual field defects through use of the Glaucoma Hemifield Test. 48 Unreliable or abnormal results are evaluated further by repeat testing. Eyes for which photographic, visual field, or clinical evaluation, or a combination thereof suggests glaucoma may be present undergo a masked review by a Glaucoma Outcomes Committee led by a glaucoma specialist or ophthalmic epidemiologist. Such eyes are followed up to make or exclude the diagnosis of glaucomatous optic nerve damage, applying the methodology used by the Baltimore Eye Survey. 49 • Cataract: The occurrence and progression of cataract is evaluated based on red reflex photographs and slit-lamp photographs, graded using an adaptation of the Age-Related Eye Diseases Study cataract grading protocol. 50 This system grades posterior subcapsular and cortical cataracts based on the percentage of lens involvement. Nuclear sclerotic cataracts are graded on the basis of optical density, using a numerical scale generated by the grader's interpolation of the optical density of the nuclear sclerosis between 4 anchor standard photographs (1.0, 2.0, 3.0, and 4.0).
Pseudophakia and aphakia are noted based on clinical examination or photography-such eyes are excluded from cataract grading. The occurrence of cataract surgery and of yttrium-aluminum-garnet laser capsulotomy or surgical capsulotomy during follow-up is noted. Whether sufficient posterior capsular opacification exists to warrant yttrium-aluminumgarnet capsulotomy, based on clinical examination alone, is noted at each visit.
• Other Ocular Complications: Other ocular complications that are expected to be uncommon, but are important with respect to evaluation of the alternative treatments, include: retinal detachment, vitreous hemorrhage, endophthalmitis, and implant extrusion.
• Hyperglycemia and Diabetes Mellitus: Fasting plasma glucose levels are measured at baseline, 3 months, 12 months, and annually thereafter. Casual plasma glucose levels are measured at all other visits. Results are interpreted using the thresholds recommended by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (American Diabetes Association) for hyperglycemia and diabetes. 51 Treatment-induced diabetes mellitus is diagnosed when a subject who is euglycemic at baseline: is observed to have diabetic-level hyperglycemia during follow-up, has medical records demonstrating that the subject was diagnosed with diabetes mellitus (with or without specification of treatment relationship) during followup, is started on therapy for diabetes mellitus, or a combination thereof. The number of oral hypoglycemic medications and use of insulin at each visit are applied to construct an ordinal scale evaluating the degree of difficulty in controlling diabetes mellitus: 0 ϭ no hypoglycemic therapy; 1 ϭ one oral hypoglycemic agent; 2 ϭ 2 or more oral hypoglycemic agents; and 3 ϭ daily use of insulin. The baseline value on this scale is subtracted from the maximum value of this scale during follow-up to indicate the change in glycemic status with therapy, allowing this outcome to be evaluated both in subjects who at baseline were nondiabetic and those who were diabetic but not requiring insulin.
• Osteoporosis: Subjects are screened for osteoporosis using dual-emission radiograph absorptiometry scanning of the spine (L2 to L4) and of the left femoral neck to measure bone mineral density at baseline and annually thereafter. Bone mineral density, the single best predictor of osteoporotic fracture risk, 52 is worsened substantially by corticosteroid therapy. 53 Generalizing the World Health Organization Study Group postmenopausal osteoporosis guidelines 54 to the setting of corticosteroid-induced bone loss-following the adaptation of the American College of Rheumatology 37 -the MUST trial defines osteopenia as a T score between Ϫ1 and Ϫ2.49 inclusive at the spine or femoral neck (whichever is worse); osteoporosis is defined as a T score of Ϫ2.5 or worse at the spine, femoral neck, or both. Fracture events, likely to be infrequent during the follow-up period of the trial, also are noted when confirmed by medical records.
• Hyperlipidemia: Fasting lipid panels-including total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein cholesterol, and triglyceride levels-are obtained at baseline, the 3-month follow-up, the 12-month follow-up, and annually thereafter. Because elevated LDL cholesterol is a major cause of coronary heart disease and is the primary target of cholesterol-lowering therapy, 55 changes in LDL cholesterol from baseline are evaluated as the main indicator of treatment effects on hyperlipidemia. Based on the categories of the National Cholesterol Education Program Expert Panel, 55 LDL cholesterol levels are categorized ordinally as follows: Ͻ 100 mg/dL, 100 to 129 mg/dL, 130 to 159 mg/dL, 160 to 189 mg/dL, and 190 mg/dL or more. The change in ordinal category from baseline is evaluated as an indicator of the effect of alternative treatments on LDL cholesterol levels. Comparisons of change in ordinal National Cholesterol Education Program category from baseline for the other lipid parameters are measured. Quantitative change in other lipid levels (e.g., high-density lipoprotein cholesterol, total cholesterol) from baseline also are evaluated.
• Hypertension: Blood pressure (BP) measurement is obtained at all clinic visits. According to the method used in the Framingham Heart Study, BP is measured twice in the seated position after a patient has rested at least 5 minutes. Measurements are obtained at least 2 minutes apart, on the left arm. The average of the 2 readings obtained is used for both systolic and diastolic BP. 56 Blood pressure stages (an ordinal scale) are evaluated in the same manner as that described for hyperlipidemia above. Based on Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommendations, 57 ordinal categories for systolic BP are: Ͻ 130 mm Hg, 130 to 139 mm Hg, 140 to 159 mm Hg, 160 to 179 mm Hg, and 180 mm Hg or more. Ordinal categories for diastolic BP are: Ͻ 85 mm Hg, 85 to 89 mm Hg, 90 to 99 mm Hg, 100 to 109, and 110 mm Hg or more. Quantitative changes in systolic BP, diastolic BP, and mean arterial pressure from baseline also are evaluated.
• Weight Gain: Weight is measured using a balance scale. Change in weight is evaluated directly and according to the body mass index (in kg/m 2 ). Change from baseline and maximum values for these variables are evaluated.
• Other Potential Systemic Complications of Corticosteroid Therapy: Other less common potential complications of systemic corticosteroid therapy are deemed to be present when medical records confirm that a diagnosis has been made. Conditions specifi-
